부신백질이영양증 치료제 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2035년)
Adrenoleukodystrophy Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2035
상품코드:1706776
리서치사:Transparency Market Research
발행일:2025년 02월
페이지 정보:영문 210 Pages
라이선스 & 가격 (부가세 별도)
한글목차
부신백질이영양증 치료제 시장 - 조사 범위
TMR의 조사 보고서 "세계 부신백질이영양증 치료제 시장"은 2025년부터 2035년까지의 예측 기간 동안 시장 지표에 대한 귀중한 인사이트를 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회를 조사하고 있습니다. 이 보고서는 2019년부터 2035년까지의 세계 부신백질이영양증 치료제 시장의 수익 및 예측을 제공하는데, 2025년을 기준 연도로, 2035년을 예측 연도로 간주하고 있습니다. 또한, 2025년부터 2035년까지 세계 부신백질이영양증 치료제 시장의 복합 연간 성장률(CAGR %)을 제시합니다.
이 보고서는 광범위한 조사를 통해 작성되었습니다. 1차 조사에서 애널리스트는 주요 오피니언 리더, 업계 리더, 오피니언 메이커를 대상으로 인터뷰를 진행했습니다. 2차 조사에서는 주요 기업의 제품 자료, 연례 보고서, 보도 자료, 관련 자료 등을 참고하여 부신백질이영양증 치료제 시장을 이해하고자 했습니다.
시장 스냅샷
2024년 시장 규모
5억 1,940만 달러
2035년 시장 규모
23억 달러
CAGR
13.9%
이 보고서는 세계 부신백질이영양증 치료제 시장의 경쟁 환경을 조사하고 있습니다. 세계 부신백질이영양증 치료제 시장에서 활동하는 주요 기업들이 확인되었으며, 각 기업들은 다양한 속성별로 프로파일링되었습니다. 회사 개요, 재무 상태, 최근 동향, SWOT는 세계 부신백질이영양증 치료제 시장 기업의 속성으로서 이 보고서에 소개되어 있습니다.
목차
제1장 서문
제2장 가정과 조사 방법
제3장 주요 요약 : 세계 시장
제4장 시장 개요
소개
개요
시장 역학
세계의 부신백질이영양증 치료제 시장 시장 분석과 예측, 2020-2035년
제5장 주요 인사이트
파이프라인 분석
지역/국가별 질환 유병률과 발증률
주요 업계 이벤트(합병, 인수, 제휴, 협업 등)
Porter's Five Forces 분석
PESTEL 분석
지역/국가별 규제 시나리오
지역/국가별 상환 시나리오
치료 선택사항과 알고리즘
신규 시장 진입자를 위한 시장 개척 전략
제6장 세계의 시장 분석과 예측 : 약제 종류별
소개와 정의
주요 조사 결과/진전
시장 금액 예측 : 약제 종류별, 2020-2035년
유전자 치료
기타
약제 종류별 시장 매력
제7장 세계의 시장 분석과 예측 : 투여 경로별
소개와 정의
주요 조사 결과/진전
시장 금액 예측 : 투여 경로별, 2020-2035년
경구
비경구
투여 경로별 시장 매력
제8장 세계의 시장 분석과 예측 : 적응증별
소개와 정의
주요 조사 결과/진전
시장 금액 예측 : 적응증별, 2020-2035년
소아기 대뇌 부신백질이영양증
애디슨병
부신척수신경병증
적응증별 시장 매력
제9장 세계의 시장 분석과 예측 : 유통 채널별
소개와 정의
주요 조사 결과/진전
시장 금액 예측 : 유통 채널별, 2020-2035년
병원 약국
소매 약국
온라인 약국
유통 채널별 시장 매력
제10장 세계의 시장 분석과 예측 : 지역별
주요 조사 결과
시장 금액 예측 : 지역별
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
지역별 시장 매력
제11장 북미의 시장 분석과 예측
미국
캐나다
제12장 유럽의 시장 분석과 예측
독일
영국
프랑스
이탈리아
스페인
기타 유럽
제13장 아시아태평양의 시장 분석과 예측
중국
인도
일본
호주와 뉴질랜드
기타 아시아태평양
제14장 라틴아메리카의 시장 분석과 예측
브라질
멕시코
기타 라틴아메리카
제15장 중동 및 아프리카의 시장 분석과 예측
GCC 국가
남아프리카공화국
기타 중동 및 아프리카
제16장 경쟁 구도
시장 기업 - 경쟁 매트릭스(기업 계층별·규모별)
시장 점유율 분석 기업별(2024년)
기업 개요
Minoryx Therapeutics
Bluebird Bio
Nutricia
Poxel SA
Orpheris, Inc.
MedDay Pharmaceuticals
Other Prominent Players
ksm
영문 목차
영문목차
Adrenoleukodystrophy Drugs Market - Scope of Report
TMR's report on the global adrenoleukodystrophy drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2025 to 2035. The report provides revenue of the global adrenoleukodystrophy drugs market for the period 2019-2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global adrenoleukodystrophy drugs market from 2025 to 2035.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the adrenoleukodystrophy drugs market.
Market Snapshot
Market Value in 2024
US$ 519.4 Mn
Market Value in 2035
US$ 2.3 Bn
CAGR
13.9%
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global adrenoleukodystrophy drugs market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global adrenoleukodystrophy drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global adrenoleukodystrophy drugs market.
The report delves into the competitive landscape of the global adrenoleukodystrophy drugs market. Key players operating in the global adrenoleukodystrophy drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global adrenoleukodystrophy drugs market profiled in this report.
Key Questions Answered in Global adrenoleukodystrophy drugs Market Report:
What is the sales/revenue generated by adrenoleukodystrophy drugs across all regions during the forecast period?
What are the opportunities in the global adrenoleukodystrophy drugs market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2035?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Adrenoleukodystrophy Drugs Market - Research Objectives and Research Approach
The comprehensive report on the global adrenoleukodystrophy drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global adrenoleukodystrophy drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2035 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global adrenoleukodystrophy drugs market.
Table of Contents
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Adrenoleukodystrophy Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Adrenoleukodystrophy Drugs Market Analysis and Forecasts, 2020-2035
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Pipeline Analysis
5.2. Disease Prevalence & Incidence Rate by Region/Countries
5.3. Key Industry Events (Mergers, Acquisitions, Partnerships, Collaborations, etc.)
5.4. PORTER's Five Forces Analysis
5.5. PESTEL Analysis
5.6. Regulatory Scenario By Region/Countries
5.7. Reimbursement Scenario By Region/Countries
5.8. Treatment Options & Algorithm
5.9. Go-to-Market Strategy for New Market Entrants
6. Global Adrenoleukodystrophy Drugs Market Analysis and Forecasts, By Drug Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Drug Type, 2020-2035
6.3.1. Gene Therapy
6.3.2. Others
6.4. Market Attractiveness By Drug Type
7. Global Adrenoleukodystrophy Drugs Market Analysis and Forecasts, By Route of Administration
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Route of Administration, 2020-2035
7.3.1. Oral
7.3.2. Parenteral
7.4. Market Attractiveness By Route of Administration
8. Global Adrenoleukodystrophy Drugs Market Analysis and Forecasts, By Indication
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Indication , 2020-2035
8.3.1. Childhood cerebral adrenoleukodystrophy
8.3.2. Addison's disease
8.3.3. Adrenomyeloneuropathy
8.4. Market Attractiveness By Indication
9. Global Adrenoleukodystrophy Drugs Market Analysis and Forecasts, By Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast By Distribution Channel , 2020-2035
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Attractiveness By Distribution Channel
10. Global Adrenoleukodystrophy Drugs Market Analysis and Forecasts, By Region
10.1. Key Findings
10.2. Market Value Forecast By Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness By Region
11. North America Adrenoleukodystrophy Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Drug Type, 2020-2035
11.2.1. Gene Therapy
11.2.2. Others
11.3. Market Value Forecast By Route of Administration, 2020-2035
11.3.1. Oral
11.3.2. Parenteral
11.4. Market Value Forecast By Indication , 2020-2035
11.4.1. Childhood cerebral adrenoleukodystrophy
11.4.2. Addison's disease
11.4.3. Adrenomyeloneuropathy
11.5. Market Value Forecast By Distribution Channel , 2020-2035
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Value Forecast By Country, 2020-2035
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Drug Type
11.7.2. By Route of Administration
11.7.3. By Indication
11.7.4. By Distribution Channel
11.7.5. By Country
12. Europe Adrenoleukodystrophy Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Drug Type, 2020-2035
12.2.1. Gene Therapy
12.2.2. Others
12.3. Market Value Forecast By Route of Administration, 2020-2035
12.3.1. Oral
12.3.2. Parenteral
12.4. Market Value Forecast By Indication , 2020-2035
12.4.1. Childhood cerebral adrenoleukodystrophy
12.4.2. Addison's disease
12.4.3. Adrenomyeloneuropathy
12.5. Market Value Forecast By Distribution Channel , 2020-2035
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Market Value Forecast By Country/Sub-region, 2020-2035
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Drug Type
12.7.2. By Route of Administration
12.7.3. By Indication
12.7.4. By Distribution Channel
12.7.5. By Country/Sub-region
13. Asia Pacific Adrenoleukodystrophy Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Drug Type, 2020-2035
13.2.1. Gene Therapy
13.2.2. Others
13.3. Market Value Forecast By Route of Administration, 2020-2035
13.3.1. Oral
13.3.2. Parenteral
13.4. Market Value Forecast By Indication , 2020-2035
13.4.1. Childhood cerebral adrenoleukodystrophy
13.4.2. Addison's disease
13.4.3. Adrenomyeloneuropathy
13.5. Market Value Forecast By Distribution Channel , 2020-2035
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.6. Market Value Forecast By Country/Sub-region, 2020-2035
13.6.1. China
13.6.2. India
13.6.3. Japan
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Drug Type
13.7.2. By Route of Administration
13.7.3. By Indication
13.7.4. By Distribution Channel
13.7.5. By Country/Sub-region
14. Latin America Adrenoleukodystrophy Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Drug Type, 2020-2035
14.2.1. Gene Therapy
14.2.2. Others
14.3. Market Value Forecast By Route of Administration, 2020-2035
14.3.1. Oral
14.3.2. Parenteral
14.4. Market Value Forecast By Indication , 2020-2035
14.4.1. Childhood cerebral adrenoleukodystrophy
14.4.2. Addison's disease
14.4.3. Adrenomyeloneuropathy
14.5. Market Value Forecast By Distribution Channel , 2020-2035
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Market Value Forecast By Country/Sub-region, 2020-2035
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Drug Type
14.7.2. By Route of Administration
14.7.3. By Indication
14.7.4. By Distribution Channel
14.7.5. By Country/Sub-region
15. Middle East & Africa Adrenoleukodystrophy Drugs Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast By Drug Type, 2020-2035
15.2.1. Gene Therapy
15.2.2. Others
15.3. Market Value Forecast By Route of Administration, 2020-2035
15.3.1. Oral
15.3.2. Parenteral
15.4. Market Value Forecast By Indication , 2020-2035
15.4.1. Childhood cerebral adrenoleukodystrophy
15.4.2. Addison's disease
15.4.3. Adrenomyeloneuropathy
15.5. Market Value Forecast By Distribution Channel , 2020-2035
15.5.1. Hospital Pharmacies
15.5.2. Retail Pharmacies
15.5.3. Online Pharmacies
15.6. Market Value Forecast By Country/Sub-region, 2020-2035
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Drug Type
15.7.2. By Route of Administration
15.7.3. By Indication
15.7.4. By Distribution Channel
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of companies)
